PDCD1 and cancer: By targeting the PD-1 (programmed cell death protein-1)/PD-L1 (programmed cell death ligand-1) pathway, ICB has demonstrated remarkable success in treating multiple types of cancers, including skin, lung, and renal cell carcinomas.